Answer
Niraparib inhibits P-glycoprotein (P-gp) in vitro and may increase systemic exposure to dabigatran etexilate, which is transported by P-gp and sensitive to intestinal P-gp inhibition, although no clinical data are available.
Sources for this answer
- Zejula 100mg TabletsGlaxoSmithKline UK · emc · SmPC §4.5 Interaction with other medicinal products · Version 8Document updated
Sources checked